Is there the possibility of vaccinating convalescent subjects from covid-19?

A phase I / II clinical trial is currently underway with the Abdala vaccine (intramuscular administration) and the Mambisa vaccine candidate (nasal administration), for the reinforcement of immunity in convalescent subjects of the viral disease covid-19. The approved study includes subjects aged 19 to 80 years, convalescing from the disease, with at least 2 months after being discharged. The Cuban regulatory authority, the Center for State Control of Medicines, Medical Equipment and Devices (CECMED) will verify compliance with good clinical practices, according to the verification programs established by the authority as part of its regulatory and oversight mission.